Get the Stockscreener App
166.29
0.03%
0.05
After Hours:
166.29
Jazz Pharmaceuticals Plc stock is traded at $166.29, with a volume of 859.12K.
It is up +0.03% in the last 24 hours and up +1.59% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$166.24
Open:
$165.5
24h Volume:
859.12K
Relative Volume:
0.74
Market Cap:
$10.10B
Revenue:
$4.16B
Net Income/Loss:
$-368.48M
P/E Ratio:
-27.39
EPS:
-6.0701
Net Cash Flow:
$1.28B
1W Performance:
+1.92%
1M Performance:
+1.59%
6M Performance:
+46.73%
1Y Performance:
+22.78%
1-Day Range:
$165.08
$168.19
1-Week Range:
$161.38
$168.19
52-Week Range:
$95.49
$182.99
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
166.29 | 10.10B | 4.16B | -368.48M | 1.28B | -6.0701 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Downgrade | UBS | Buy → Neutral |
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
LSV Asset Management Sells 41,884 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026 - GlobeNewswire Inc.
Is the Options Market Predicting a Spike in Jazz Pharmaceuticals Stock? - Yahoo Finance
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 - PR Newswire UK
Essex Investment Management Co. LLC Invests $2.70 Million in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals (JAZZ) Valuation After HERIZON GEA Trial Upside And Planned 2026 sBLA Filing - simplywall.st
Renaissance Group LLC Sells 7,254 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Lupin Receives Tentative Approval from U.S. FDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral SolutionLupin | Press Release - lupin.com
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How HERIZON-GEA’s First-Line GEA Data And sBLA Plan At Jazz Pharmaceuticals (JAZZ) Has Changed Its Investment Story - simplywall.st
The Best Biotech Stocks to Buy - Morningstar
Allianz Asset Management GmbH Purchases 30,537 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Zacks Research Brokers Lower Earnings Estimates for JAZZ - MarketBeat
New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings - Yahoo Finance
What is Zacks Research's Estimate for JAZZ Q1 Earnings? - MarketBeat
Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial - Insider Monkey
Strs Ohio Sells 14,393 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals plc (JAZZ): Investor Outlook with a 32% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
What is the target price for Jazz Pharmaceuticals plc stockMarket Risk Analysis & High Win Rate Trade Tips - baoquankhu1.vn
Autistic Disorder Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Jazz Pharma, Axial Therapeutics, Eli Lilly and Company, Scioto Bioscienc - Barchart.com
Autistic Disorder Pipeline 2025: Therapies Under - openPR.com
Top Investors’ Stock Portfolio: 10 Mid-cap Stocks To Buy - Insider Monkey
The Truth About Jazz Pharmaceuticals: Why Wall Street Suddenly Can’t Shut Up - AD HOC NEWS
Is Jazz Pharmaceuticals (JAZZ) Offering An Opportunity After Recent Share Price Pullback - Yahoo Finance
Is Jazz Pharmaceuticals (JAZZ) Offering Opportunity After A 32% One Year Share Price Gain - simplywall.st
These 4 Measures Indicate That Jazz Pharmaceuticals (NASDAQ:JAZZ) Is Using Debt Reasonably Well - 富途牛牛
Jazz Pharmaceuticals PLC $JAZZ Shares Bought by Great Lakes Advisors LLC - MarketBeat
Lewy Body Dementia Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Jazz Pharma, Allergan, Noven Pharma, Takeda Pharma, Eli Lilly, Mallinckrodt - Barchart.com
Mitsubishi UFJ Trust & Banking Corp Raises Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Aug Weekly: Is ADPT a good ESG investmentStop Loss & Stock Portfolio Risk Management - baoquankhu1.vn
Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? - Finviz
Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026? - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Stock Analysis: Unpacking A Promising 28% Upside Potential - DirectorsTalk Interviews
How Boehringer Ingelheim Oncology Collaboration Could Shape Jazz Pharmaceuticals' (JAZZ) Dual HER2 Strategy - simplywall.st
Universal Beteiligungs und Servicegesellschaft mbH Cuts Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After New Boehringer Ingelheim Oncology Collaboration - simplywall.st
Aug Update: Should I invest in Kaltura Inc before earningsEarnings Miss & Intraday High Probability Alerts - baoquankhu1.vn
Dip Buying: Why is Jazz Pharmaceuticals plc stock going upEarnings Risk Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Acute Myeloid Leukemia Market Forecast to 2034: 7MM Opportunity, Strong CAGR, 43,500 Annual Cases, and Pipeline-Driven Growth | DelveInsight - Barchart.com
Lmcg Investments LLC Trims Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Aug Mood: Will Jazz Pharmaceuticals plc benefit from green energy policiesTrade Exit Report & Community Consensus Stock Picks - baoquankhu1.vn
Jazz Pharmaceuticals (JAZZ) Is Up 5.1% After Monetizing FDA Voucher And Expanding Oncology Collaboration - Yahoo Finance
Is Jazz (JAZZ) Quietly Recasting Its Oncology Strategy Through HER2 Partnerships And Voucher Monetization? - simplywall.st
New York State Teachers Retirement System Sells 9,223 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug - MSN
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Momentum - simplywall.st
JPM26: Jazz sells PRV for $200m, targets deals in 2026 - Pharmaceutical Technology
JAZZJazz Pharmaceuticals Plc Latest Stock News & Market Updates - Stock Titan
Jazz Sells Priority Review Voucher for $200M as Program’s Renewal Languishes in Senate - BioSpace
Jazz Pharmaceuticals stock rating reiterated at Outperform by RBC Capital - Investing.com Nigeria
Jazz Pharmaceuticals Soars with Promising HERIZON-GEA-01 Results - timothysykes.com
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):